To avoid systemic side effects and to achieve active targeted delivery, we modified EVs with Lamp2b-E7 to target hBMMSCs and alternatively with Lamp2b-Her2 to target CRC cells, to release circp53 at the tumor site with spatial and temporal selectivity using the affinity peptide. The gene discussed is ERBB2; the disease is neoplasm.